S-4 Filing

The deal is expected to close in the first quarter of 2023.

This would be at least the 9th extension, if approved.

After facing a market delisting earlier this summer, the Nasdaq in June agreed to give AGBA until November to complete a deal.

Getting this deal across the finish line has been a struggle. Redemptions ahead of deadline extension votes in January and July 2022 wiped out 82.85% of the SPAC's cash in trust. ACE is down to about $40.5 million in trust. Ace last month disclosed in a regulatory filing that PIPE investor Oaktree had terminated a $175 million investment.

A merger agreement with Jakarta-based Traveloka collapsed in June.

Lux Health earlier this month said it entered into a non-binding letter of intent for a business combination with an unnamed life sciences company.

10X in the filing said management is in discussions about other potential merger opportunities, but won't be able to close a deal by the current deadline in two months.

Aesther raised $105 million in a September 2021 IPO and has secured a $40 million backstop on the deal, which has an enterpirse value of $345 million.

If approved, this would be the SPAC's 6th extension. Redemptions on the 5th extension vote, in July, came to 1,025,281 shares, or about 18%.

The transaction would result in gross proceeds of $16 million, less any redemptions and expenses.